الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 119 |  |  |
| | | from | 119 | | |
Abstract
Introduction: Acute leukemia is classified as myeloid or lymphoid leukemia based on the morphologic characteristics, cytochemistry and a panel of immunologic markers of the roliferating blast cells. AML is the most frequent form of acute leukemia in adult. , little is known about the clinical impact of plasma galectin-3 level in AMLThe aim of work: Concentration of plasma galectin-3 in non M3 AML patients and healthy control sample. Effect of galectin-3 levels on treatment response and prognosisResearch Plan: This prospective study enrolled on newly diagnosed non M3 acute myeloid leukemia patients that presented to OPC Oncology Center, Mansoura University with minimum follow up period of at least 1 year. Diagnosis and classification were confirmed on basis of FAB and WHO criteria. 69 patients with acute myeloid leukemia except M3 from Mansoura Oncology Center were randomly included in this study.36 males and 33 females. with age ranged from 18 to 81 years. Twenty subjects were included as control group. Blood samples were taken from patients and controls: Results: CR was achieved in fifty three (78.8%) while sixteen(23.2%) didn’t acheive 1st complete remission. from fifty three patients who achieve 1st CR ,twenty one patient relapsed (39%) incontrast to thirty two patient (60%) didn’t relapse . Galectin-3 was significantly high in patients that didn’t achieve 1st CR after induction chemotherapy with value 6.5±1.2 vs patients that achieved 1st CR 5.4±1.3 with significant P value 0.005. Galectin-3 was significantly high in patients that didn’t achieve 1st CR after induction chemotherapy with value 6.5±1.2 vs patients that achieved 1st CR 5.4±1.3 with significant P value 0.005.Conclusion:Galectin-3 may serve as a new biomarker for predicting clinical outcomes in AML patients, and may serve as a prospective therapeutic target in patients with higher expression of this protein.